An evaluation of the in vitro activity of terbinafine

References

• Ryder NS, Favre B. Antifungal activity and mechanism of action of terbinafine. Rev Contemp Pharmacot her 1997; 8: 275–287.
   Google Scholar
• Ryder NS, Mieth H. Allylamine antifungal drugs. Curr Top Med Mycol 1992; 4: 158–188.
   PubMedGoogle Scholar
• Ryder NS, Wagner S, Leitner I. In vitro activities of terbinafine against cutaneous isolates of Candida albi cans and other patho-genic yeasts. Antimicrob Agents Chemother 1998; 424 1057–1061.
   Google Scholar
• Arzeni D, Barchiesi F, Compagnucci P, et al. In vitro activity of terbinafine against clinical isolates of dermatophytes. Medical Mycology 1998; 36: 235–237.
   PubMedGoogle Scholar
• National Committee for Clinical Laboratory Standards. Refer-ence method for broth dilution antifungal susceptibility testing of yeasts. Approved standard. NCCLS document M27-A Wayne, PA: National Committee for Clinical Laboratory Stan-dards, 1997.
   Google Scholar
• Clayton YM. The in vitro activity of terbinafine against uncom-mon fungal pathogens. In: Fromtling RA, ed. Recent Trends in the Discovery, Development and Evaluation of Antifungal agents. Barcelona: J.R. Prous Science Publishers, 1987: 433–439.
   Google Scholar
• Clayton YM. Relevance of broad-spectrum and fungicidal ac-tivity of antifungals in the treatment of dermatomycoses. Br J Dermatol 1994; 130 (Suppl. 43): 7–8.
   Google Scholar
• Goudard M, Cordier C, Regli P. Sensibilité des Fusarium aux antifongiques: essais in vitro. Bull Soc Fr Mycol Med 1988a; 17: 199–202.
   Google Scholar
• Rubio MC, Gil J, Rezusta A, Bueno MR, Bueno R. In vitro evaluation of three new antifungal agents: amorolfine (Ro 14-4767/002), terbinafine (SF 86-327) and itraconazole (R 51,211). Rev Esp Quimioterap 1993; 6: 125–139.
   Google Scholar
• Venugopal PV, Venugopal TV. Antifungal activity of ally-lamine derivatives. Indian J Med Res 1994; 99: 71–73.
   PubMedGoogle Scholar
• Meingassner JG, Frei R, Leitner I. Activity of terbinafine against isolates of Paecilomyces lilacinus resistant to ampho-tericin B, miconazole, fluconazole and itraconazole. Second International Summit on Cutaneous Antifungal Therapy, Boston, November 11–13, 1994. Cleveland, OH: Case Western Reserve University, 1994: Abstract 15.
   Google Scholar
• Shadomy S, Espinell-Ingroff A, Gebhart RJ. In vitro studies with SF 86-327, a new orally active allylamine derivative. Sabouraudia 1985; 23: 125–132.
   PubMedGoogle Scholar
• Ahmad A, Khan AK, Sultana S, Siddiqi SA, Haroon TS. In vitro antifungal studies of terbinafine. Pakistan J Sci Ind Res 1989; 32: 737–739.
   Google Scholar
• Goudard M, Buffard Y, Ferrari H, Regli P. Spectre d'action in vitro d'un nouvel antifungique derive de la naftifine: la ter-binafine (SF 86-327). Pathol Biol (Paris) 1986; 34: 680–683.
   PubMedGoogle Scholar
• Hiratani T, Asagi Y, Yamaguchi H. Evaluation of in vitro antimycotic activity of terbinafine, a new allylamine agent. Jpn J Med Mycol 1991; 3/ 323–332.
   Google Scholar
• Petranyi G, Meingassner JG, Mieth H. Antifungal activity of the allylamine derivative terbinafine in vitro. Antimicrob Agents Chemother 1987; 31: 1365–1368. @ 2000 1SHAM, Medical Mycology, 38, 155-159
   Google Scholar
• Bryan CS, Smith CW, Berg DE, Karp RB. Curvularia lunata endocarditis treated with terbinafine-case report. Clin Infect Dis 1993; 16: 30–32.
   PubMedGoogle Scholar
• Goudard M, Regli P, Buffard Y, Gabriel B. Sensibilitê in vitro des Aspergillus a la terbinafine: etude comparative avec l'am-photericine B, la 5-fluorocytosine et le ketoconazole. Pathol Biol (Paris) 1988b; 36: 129–143.
   Google Scholar
• Schmitt HJ, Bernard EM, Andrade J, Edwards F, Schmitt B, Armstrong D. MIC and fungicidal activity of terbinafine against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother 1988; 32: 780–781.
   PubMed Web of Science ®Google Scholar
• Wong PK, Ching WTW, Kwon-Chung KJ, Meyer RD. Dis-seminated Phialophora parasitica infection in humans: case report and review. Rev Infect Dis 1989; 11: 770–775.
   PubMedGoogle Scholar
• Venugopal PV, Venugopal TV, Ramakrishna ES, Ilavarasin S. Antifungal activity of allylamines against agents of eumyce-toma. Indian J Dermatol Venereol Leprol 1993; 59: 239–242.
   Google Scholar
• Polak A, Dixon DM. Loss of melanin in Wangiella dermatiditis does not result in greater susceptibility to antifungal agents. Antimicrob Agents Chemother 1989; 33: 1639–1640.
   PubMed Web of Science ®Google Scholar
• Dixon DM, Polak A. In vitro and in vivo drug studies with three agents of central nervous system phaeohyphomycosis. Chemotherapy 1987; 33: 129–140.
   PubMed Web of Science ®Google Scholar
• De Hoog GS, Matsumoto T, Matsuda T, Uijthof JMJ. - ophiala jeanselmei var. lecanii-corni, an etiologic agent of hu-man phaeohyphomycosis, with report of a case. J Med Vet Mycol 1994; 32: 373–380.
   Google Scholar
• Venugopal PV, Venugopal TV. Disk diffusion susceptibility testing of dermatophytes with allylamines. Int J Dermatol 1994; 33: 730–732.
   PubMedGoogle Scholar
• Butty P, Lebecq JC, Mallie M, Bastide JM. Evaluation of the susceptibility of dennatophytes to antifungal drugs: a new technique. J Med Vet Mycol 1995; 33: 403–409.
   PubMedGoogle Scholar
• Ryder NS, Leitner L Activity of terbinafine against Aspergillus in vitro, in combination with amphotericin B or triazoles. 36' Interscience Conference on Antimicrobial Agents and Chemother-apy. New Orleans, LA, 15–18 September 1996. Washington DC: American Society for Microbiology, 1996: Abstract E54.
   Google Scholar
• Jensen JC. Clinical pharmacokinetics of terbinafine. Clin Exp Dermatol 1989; 14: 110–114.
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Kirkesseli S, Humbert H, Grass P, Kutz K. Dose-proportional pharmacokinetics of terbinafine and its N-demethylatekl metabolite in healthy volunteers. Br J Dermatol 1992; 126 (Suppl. 39): 8–13.
   Google Scholar
• Ryder NS, Dupont. MC. Inhibition of squalene epoxidase by allylamine antimycotic compounds: a comparative study of the fungal and mammalian enzymes. Biochem J 1985; 230: 765–770.
   PubMed Web of Science ®Google Scholar
• Rex JH, Pfaller MA, Galgiani JN, et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual Framework and analysis of in vitro-in vivo correla-tion data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis 1997; 24: 235–247.
   PubMed Web of Science ®Google Scholar